Top RNA Therapeutic Safety Risks—and How Preclinical Research Is Helping Address Them
Kate Green
By Jane Lindborg, Study Director & Research Scientist RNA-based therapies have moved rapidly from theoretical promise to clinical reality. Today, mRNA, siRNA, antisense oligonucleotides (ASOs), and other RNA modalities are being explored across oncology, rare disease, inflammatory conditions, and beyond. While these approaches offer powerful advantages—including speed of design and manufacturing—RNA therapeutics also present unique safety challenges. Many of these risks ... Read More The post T